Hypereosinophilic syndrome is defined by persistent eosinophilia with eosinophil-mediated organ/tissue damage, driving ...
In today's Pharmaceutical Executive Daily, the FDA grants accelerated approval to BeOne Medicines' Beqalzi as the first and only BCL2 inhibitor for relapsed or refractory mantle cell lymphoma, while ...
In the first part of her interview with Pharmaceutical Executive, Sandra Coufal, MD, CEO of Toragen, explains why the HPV E5 ...
The current prior authorization (PA) process is an administrative failure. Beyond the excessive time and paperwork required, ...
Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...
Phase IIIb SURMOUNT-Maintain showed near-complete weight-loss maintenance on maximum tolerated tirzepatide through Week 112, while a 5 mg step-down dose was associated with 5.6 kg mean regain.
Veppanu leverages PROTAC-mediated ubiquitin–proteasome degradation to eliminate mutant estrogen receptor, aiming to bypass ESR1-driven endocrine resistance rather than merely inhibiting receptor ...
White House sources indicate Trump approved Makary’s removal, reflecting escalating senior leadership churn across federal health agencies. Makary’s tenure featured MAHA-aligned regulatory positions, ...
Madrigal Pharmaceuticals entered an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a ...
TRuE-AD4 enrolled adults with 10%–20% BSA moderate atopic dermatitis and prior inadequate response, intolerance, or ...
Robert F. Kennedy reportedly initiated Makary’s ouster, and the White House signed off, underscoring HHS-driven influence over FDA leadership and the agency’s near-term policy direction. Kyle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results